iPierian Inc. Announces Oral Presentation Of Tau Antibody Preclinical Efficacy Study Which Showed Significant Reduction In Alzheimer’s Disease Progression
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--iPierian, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, announced today the presentation of a preclinical study of their Tau antibody program that demonstrated the inhibition of global disease progression of Alzheimer’s disease across numerous endpoints and multiple brain regions. The promising in vivo efficacy results relate to iPierian’s lead antibody drug candidate, IPN007, which targets the Tau protein, and were described in an oral presentation at the Society for Neuroscience annual meeting in San Diego, CA. Based on this study, as well as additional in vitro and in vivo preclinical data and achievements in developing the IPN007 humanized antibody, iPierian plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in 2014.
Help employers find you! Check out all the jobs and post your resume.